Publications by authors named "Roger B Cohen"

100Publications

Bayesian approach to interpreting somatic cancer sequencing data: a case in point.

J Clin Pathol 2020 Aug 27. Epub 2020 Aug 27.

Department of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA

View Article and Find Full Text PDF
August 2020

Management of Lung Cancer During the COVID-19 Pandemic.

JCO Oncol Pract 2020 Sep 26;16(9):579-586. Epub 2020 May 26.

Division of Hematology/Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA.

View Article and Find Full Text PDF
September 2020

Care of immunocompromised patients with head and neck cancer during the COVID-19 pandemic: Two challenging and informative clinical cases.

Head Neck 2020 06 22;42(6):1131-1136. Epub 2020 Apr 22.

Department of Otorhinolaryngology: Head and Neck Surgery, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

View Article and Find Full Text PDF
June 2020

Immunotherapy for head and neck cancer: where are we now and where are we going?

Ann Transl Med 2019 Jul;7(Suppl 3):S75

Division of Hematology Oncology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.

View Article and Find Full Text PDF
July 2019

Treatment and Outcomes of Oropharyngeal Cancer in People with Human Immunodeficiency Virus.

AIDS Res Hum Retroviruses 2019 10 29;35(10):934-940. Epub 2019 Aug 29.

Division of Infectious Diseases, Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.

View Article and Find Full Text PDF
October 2019

Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells.

Cell 2018 12 29;175(7):1731-1743.e13. Epub 2018 Nov 29.

Innate Pharma, 117 Avenue de Luminy, 13009 Marseille, France; Aix Marseille Université, INSERM, CNRS, Centre d'Immunologie de Marseille-Luminy, 13009 Marseille, France; Service d'Immunologie, Marseille Immunopole, Hôpital de la Timone, Assistance Publique-Hôpitaux de Marseille, 13005 Marseille, France. Electronic address:

View Article and Find Full Text PDF
December 2018

Barriers to physical activity: a study of academic and community cancer survivors with pain.

J Cancer Surviv 2018 12 4;12(6):744-752. Epub 2018 Sep 4.

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

View Article and Find Full Text PDF
December 2018

The association between fatigue and pain symptoms and decreased physical activity after cancer.

Support Care Cancer 2018 Oct 19;26(10):3423-3430. Epub 2018 Apr 19.

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

View Article and Find Full Text PDF
October 2018

Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma: Findings of the Phase 1b KEYNOTE-028 Study.

Am J Clin Oncol 2018 Nov;41(11):1083-1088

*University of Pennsylvania, Philadelphia, PA †Institut Claudius Regaud, Toulouse §§U900 INSERM Research Unit, Saint-Cloud ‡‡Institut Curie, Paris ##Gustave Roussy, Villejuif, France ‡National Cancer Center Hospital East, Chiba, Japan §The University of Texas MD Anderson Cancer Center, Houston, TX ∥Georgetown University Hospital, Washington, DC ¶Vanderbilt University School of Medicine, Nashville, TN #Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA **Fondazione IRCCS Istituto Nazionale dei Tumori Medical Oncology, Milan, Italy ††National Taiwan University Hospital, Taipei, Taiwan ∥∥Princess Margaret Cancer Centre ¶¶Ontario Institute for Cancer Research, Toronto, ON, Canada ***Vall d'Hebron Institute of Oncology, Barcelona, Spain †††Maryland Oncology Hematology PA, Rockville, MD ‡‡‡Merck & Co. Inc., Kenilworth, NJ §§§Seoul National University Hospital, Seoul, Republic of Korea.

View Article and Find Full Text PDF
November 2018

Effect of Prophylactic Cranial Irradiation on Overall Survival in Metastatic Small-Cell Lung Cancer: A Propensity Score-Matched Analysis.

Clin Lung Cancer 2018 05 14;19(3):260-269.e3. Epub 2017 Dec 14.

Department of Radiation Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA. Electronic address:

View Article and Find Full Text PDF
May 2018

Circulating tumor cells as a predictive biomarker in patients with small cell lung cancer undergoing chemotherapy.

Lung Cancer 2017 10 12;112:118-125. Epub 2017 Aug 12.

Janssen Diagnostics, LLC, Huntingdon Valley, PA, United States; Division of Pulmonary and Critical Care, Thoracic Oncology Group, University of Pennsylvania, Philadelphia, PA, United States.

View Article and Find Full Text PDF
October 2017

Etirinotecan Pegol (NKTR-102) in Third-line Treatment of Patients With Metastatic or Recurrent Non-Small-cell Lung Cancer: Results of a Phase II Study.

Clin Lung Cancer 2018 03 19;19(2):157-162. Epub 2017 Oct 19.

Hematology-Oncology Division, Department of Medicine, Perelman Center for Advanced Medicine, University of Pennsylvania, Philadelphia, PA.

View Article and Find Full Text PDF
March 2018

Emerging uses of circulating tumor DNA in advanced stage non-small cell lung cancer.

Ann Transl Med 2017 Sep;5(18):380

Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.

View Article and Find Full Text PDF
September 2017

Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study.

J Clin Oncol 2017 Dec 24;35(36):4050-4056. Epub 2017 Aug 24.

Chiun Hsu, National Taiwan University Hospital, Graduate Institute of Oncology, National Taiwan University College of Medicine, and National Taiwan University Cancer Center, Taipei, Taiwan, Republic of China; Se-Hoon Lee, Seoul National University Hospital, Seoul, South Korea; Samuel Ejadi, Virginia G. Piper Cancer Center, Scottsdale, AZ; Roger B. Cohen, University of Pennsylvania, Philadelphia, PA; Janice M. Mehnert, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ; Alain Algazi, University of California, San Francisco, San Francisco, CA; Sanatan Saraf, Pradeep Thanigaimani, and Jonathan D. Cheng, Merck & Co., Inc., Kenilworth, NJ; Caroline Even, Gustave Roussy, Villejuif; Christophe Le Tourneau, Institut Curie, Paris; Christophe Le Tourneau, INSERM U900 Research Unit, Saint-Cloud, France; Emilie M.J. van Brummelen, Netherlands Cancer Institute, Amsterdam, the Netherlands; and Aaron R. Hansen, Princess Margaret Cancer Centre, Toronto, ON, Canada.

View Article and Find Full Text PDF
December 2017

Combining immunotherapy and radiation therapy for small cell lung cancer and thymic tumors.

Transl Lung Cancer Res 2017 Apr;6(2):186-195

Division of Hematology-Oncology, Perelman Center for Advanced Medicine, Philadelphia, USA.

View Article and Find Full Text PDF
April 2017

Beyond Positive Margins and Extracapsular Extension: Evaluating the Utilization and Clinical Impact of Postoperative Chemoradiotherapy in Resected Locally Advanced Head and Neck Cancer.

J Clin Oncol 2017 May 13;35(14):1550-1560. Epub 2017 Feb 13.

Daniel M. Trifiletti and Paul Read, University of Virginia, Charlottesville, VA; Andrew Smith, Nandita Mitra, Surbhi Grover, John N. Lukens, Roger B. Cohen, Alexander Lin, and Samuel Swisher-McClure, University of Pennsylvania, Philadelphia, PA; and William M. Mendenhall, University of Florida, Gainesville, FL.

View Article and Find Full Text PDF
May 2017

Pretreatment Red Blood Cell Total Folate Concentration Is Associated With Response to Pemetrexed in Stage IV Nonsquamous Non-Small-cell Lung Cancer.

Clin Lung Cancer 2017 03 26;18(2):e143-e149. Epub 2016 Oct 26.

Center of Excellence in Environmental Toxicology and Center for Cancer Pharmacology, Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.

View Article and Find Full Text PDF
March 2017

Scan-associated distress in lung cancer: Quantifying the impact of "scanxiety".

Lung Cancer 2016 10 16;100:110-113. Epub 2016 Aug 16.

Abramson Cancer Center at the University of Pennsylvania, Philadelphia, PA, United States; Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States.

View Article and Find Full Text PDF
October 2016

Immunotherapy for head and neck cancer: latest developments and clinical potential.

Ther Adv Med Oncol 2016 May 16;8(3):168-75. Epub 2016 Feb 16.

Department of Medicine, Division of Hematology-Oncology, University of Pennsylvania, 624 South Pavilion, Perelman Center for Advanced Medicine, 3400 Civic Center Boulevard, Philadelphia, PA 19104, USA.

View Article and Find Full Text PDF
May 2016

Capecitabine and lapatinib for the first-line treatment of metastatic/recurrent head and neck squamous cell carcinoma.

Cancer 2016 08 19;122(15):2350-5. Epub 2016 May 19.

Division of Hematology and Oncology, University of Pennsylvania, Abramson Comprehensive Cancer Center, Philadelphia, Pennsylvania.

View Article and Find Full Text PDF
August 2016

Acupuncture for Dyspnea in Lung Cancer: Results of a Feasibility Trial.

Integr Cancer Ther 2016 09 24;15(3):326-32. Epub 2016 Apr 24.

Abramson Cancer Center at the University of Pennsylvania, Philadelphia, PA Department of Family Medicine and Community Health, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.

View Article and Find Full Text PDF
September 2016

Cancer Communication in the Social Media Age.

JAMA Oncol 2016 Jun;2(6):822-3

Abramson Cancer Center, University of Pennsylvania, Philadelphia3Crescenz VA Medical Center, Philadelphia, Pennsylvania.

View Article and Find Full Text PDF
June 2016

Statistical Considerations in Clinical Trial Design of Immunotherapeutic Cancer Agents.

J Immunother 2015 Sep;38(7):259-66

*Heat Biologics Inc., Durham, NC †Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA ‡Drug Development Office, Cancer Research UK, London, UK §Division of Medical Oncology, Princess Margaret Cancer Center, Toronto, ON, Canada ∥Department of Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, FL.

View Article and Find Full Text PDF
September 2015

Phase I dose-escalation study of cabazitaxel administered in combination with gemcitabine in patients with metastatic or unresectable advanced solid malignancies.

Anticancer Drugs 2015 Aug;26(7):785-92

aDivision of Hematology/Oncology, University of New Mexico Cancer Center, Albuquerque, New Mexico bDivision of Hematology-Oncology, Henry-Joyce Cancer Clinic/The Vanderbilt Clinic, Nashville, Tennessee cYale Cancer Center, Yale University, New Haven, Connecticut dFox Chase Cancer Center, Philadelphia, Pennsylvania eDepartment of Medicine, Division of Hematology-Oncology, University of Cincinnati Cancer Institute, Cincinnati, Ohio fSanofi, Bridgewater, New Jersey, USA gSanofi, Montpellier, France.

View Article and Find Full Text PDF
August 2015

Phase I study of the safety and pharmacokinetics of trabectedin with docetaxel in patients with advanced malignancies.

Cancer Chemother Pharmacol 2015 May 20;75(5):1047-55. Epub 2015 Mar 20.

Department of Medical Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA, 19111, USA,

View Article and Find Full Text PDF
May 2015

Evaluating the safety and efficacy of axitinib in the treatment of advanced renal cell carcinoma.

Cancer Manag Res 2015 11;7:65-73. Epub 2015 Feb 11.

Department of Medicine, Division of Hematology and Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.

View Article and Find Full Text PDF
February 2015

Phase I dose-escalation study of LCL161, an oral inhibitor of apoptosis proteins inhibitor, in patients with advanced solid tumors.

J Clin Oncol 2014 Oct 11;32(28):3103-10. Epub 2014 Aug 11.

Jeffrey R. Infante, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; E. Claire Dees, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC; Antony J. Olszanski, Fox Chase Cancer Center; Roger B. Cohen, Perelman School of Medicine, Philadelphia, PA; Shyeilla V. Dhuria and Suman Sen, Novartis Pharmaceuticals Corp, East Hanover, NJ; and Scott Cameron, Novartis Institutes for Biomedical Research, Cambridge, MA.

View Article and Find Full Text PDF
October 2014

Late consequential surgical bed soft tissue necrosis in advanced oropharyngeal squamous cell carcinomas treated with transoral robotic surgery and postoperative radiation therapy.

Int J Radiat Oncol Biol Phys 2014 Aug 10;89(5):981-988. Epub 2014 Jun 10.

Department of Radiation Oncology, University of Pennsylvania, Philadelphia, Pennsylvania; Department of Otorhinolaryngology-Head and Neck Surgery, University of Pennsylvania, Philadelphia, Pennsylvania; Johns Hopkins University, Baltimore, Maryland. Electronic address:

View Article and Find Full Text PDF
August 2014

A multicenter phase 1 study of PX-866 and cetuximab in patients with metastatic colorectal carcinoma or recurrent/metastatic squamous cell carcinoma of the head and neck.

Invest New Drugs 2014 Dec 12;32(6):1197-203. Epub 2014 Jun 12.

Division of Medical Oncology, University of Colorado School of Medicine, 12801 East 17th Avenue MS 8117 Aurora, Denver, CO, 80045, USA,

View Article and Find Full Text PDF
December 2014

Phase I safety and pharmacokinetic study of the PI3K/mTOR inhibitor SAR245409 (XL765) in combination with erlotinib in patients with advanced solid tumors.

J Thorac Oncol 2014 Mar;9(3):316-23

*Lowe Center for Thoracic Oncology and the Belfer Institute for Applied Cancer Science, Dana Farber Cancer Institute, Boston, Massachusetts; †Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania; ‡Translational Medicine, Exelixis, Inc., South San Francisco, San Francisco, California; §Translational and Experimental Medicine, Sanofi, Vitry-sur-Seine, France; ‖Center for Thoracic Centers, Massachusetts General Hospital Cancer Center, Charlestown, Massachusetts; ¶Clinical Development Oncology, Sanofi, Cambridge, Massachusetts; #Pharmacokinetic Modeling and Simulation, Sanofi, Cambridge, Massachusetts; **Biostatistics and Programming, Sanofi, Cambridge, Massachusetts; ††Early Drug Development Center, Dana-Farber Cancer Institute, Boston, Massachusetts; ‡‡Department of Medical Oncology, Vall d'ebron University Hospital, Barcelona, Spain.

View Article and Find Full Text PDF
March 2014

Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)- and ErbB family-targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC).

Authors:
Roger B Cohen

Cancer Treat Rev 2014 May 12;40(4):567-77. Epub 2013 Oct 12.

Abramson Cancer Center, Philadelphia, PA, United States. Electronic address:

View Article and Find Full Text PDF
May 2014

A phase I dose-finding, safety and tolerability study of AZD8330 in patients with advanced malignancies.

Eur J Cancer 2013 May 21;49(7):1521-9. Epub 2013 Feb 21.

Division of Hematology and Oncology, Department of Medicine, Fox Chase Cancer Center, Philadelphia, PA, USA.

View Article and Find Full Text PDF
May 2013

Antiangiogenic therapy for advanced renal cell carcinoma: management of treatment-related toxicities.

Invest New Drugs 2012 Oct 12;30(5):2066-79. Epub 2012 Feb 12.

Division of Hematology/Oncology, University of Pennsylvania, Philadelphia, PA 19104, USA.

View Article and Find Full Text PDF
October 2012

Pharmacokinetic evaluation of axitinib.

Expert Opin Drug Metab Toxicol 2012 Feb 17;8(2):259-70. Epub 2012 Jan 17.

Phase I Clinical Trials Fox Chase Cancer Center-Medical Oncology, 333 Cottman Avenue, Philadelphia, PA 19111, USA.

View Article and Find Full Text PDF
February 2012

The contribution of cetuximab in the treatment of recurrent and/or metastatic head and neck cancer.

Biologics 2010 Aug 9;4:173-85. Epub 2010 Aug 9.

Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA.

View Article and Find Full Text PDF
August 2010

Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors.

Cancer Chemother Pharmacol 2011 Apr 7;67(4):945-54. Epub 2010 Jul 7.

UNC Lineberger Comprehensive Cancer Center, University of North Carolina, 170 Manning Drive, 3rd floor POB, CB 7305, Chapel Hill, NC 27599, USA.

View Article and Find Full Text PDF
April 2011